Recombinant Human Albumin Injection (Oryza Sativa)
Albumin therapy (e.g., hypoproteinemia, volume expansion)
Phase 3Active
Key Facts
Indication
Albumin therapy (e.g., hypoproteinemia, volume expansion)
Phase
Phase 3
Status
Active
Company
About Healthgen Biotechnology
Healthgen Biotech develops recombinant proteins using a rice-based expression platform, with a lead albumin therapy in Phase III and products for bioprocessing and cosmetics.
View full company profile